Reduced risk was more pronounced in those with type 2 diabetes, but was also seen in those without T2D<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
WEDNESDAY, Oct. 9, 2024 (HealthDay News) — For individuals with obesity, metabolic-bariatric surgery (MBS) is associated with a reduced risk for pancreatic cancer, especially among those with type 2 diabetes (T2D), according to a review published online Oct. 9 in Diabetes\/Metabolism Research and Reviews<\/em>.<\/p>\n Angeliki M. Angelidi, M.D., Ph.D., from the Broad Institute of MIT and Harvard in Cambridge, Massachusetts, and colleagues conducted a systematic review and meta-analysis to examine the impact of MBS on pancreatic cancer risk in individuals with obesity, based on T2D status. Data were included from 12 studies, with 3,711,243 participants.<\/p>\n The researchers found that for both the T2D group and the overall population, pancreatic cancer risk was lower in the MBS group than the non-MBS group (risk ratios, 0.46 and 0.21, respectively); after excluding studies with less than three years of follow-up, the findings were consistent. In individuals without T2D, a favorable impact was also seen (risk ratio, 0.56). When comparing types of MBS versus control, there was a significant difference for sleeve gastrectomy and a nonsignificant improvement for Roux-en-Y gastric bypass.<\/p>\n “Our study showed that \u039cBS is associated with decreased pancreatic cancer risk in individuals with obesity irrespective of T2D,” the authors write. “Furthermore, our findings suggest that there may be a more pronounced effect of MBS in patients with T2D, highlighting the potential preventive advantages of MBS in this population.”<\/p>\n